Ultragenyx Pharmaceutical Q2 EPS $(0.90) Beats $(1.51) Estimate, Sales $214.000M Beat $158.777M Estimate
Ultragenyx Pharmaceutical (NASDAQ:RARE) reported quarterly losses of $(0.90) per share which beat the analyst consensus estimate of $(1.51) by 40.4 percent. This is a 23.08 percent increase over losses of $(1.17) per
